| Latest Onyx Pharmaceuticals News Headlines | | Date | Time | Source | | | 11/16/2009 | 9:29AM | PRNUS | Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
EMERYVILLE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment... More...>> |
| 11/11/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
EMERYVILLE, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested parties may access a live webcast... More...>> |
| 11/10/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and ONX 0803 at 51st American Society of Hematology A
EMERYVILLE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the... More...>> |
| 11/03/2009 | 4:06PM | PRNUS | Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over
Non-GAAP Net Income of $22 Million, 34% Increase Over Third Quarter 2008
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today reported its financial results for the third quarter 2009. Global Nexavar net sales as reported by Onyx's collaborator Bayer HealthCare Pharmaceuticals... More...>> |
| 11/02/2009 | 9:31AM | PRNUS | Seven Summits Research Releases Comments on Qualcomm, Onyx Pharmaceuticals, XTO Energy, Prudential and Intercontinental Exchange
CHICAGO, Nov. 2 /PRNewswire/ -- Seven Summits Strategic Investments releases its Stocks To Watch Guide.
The Seven Summits Strategic Investments Stocks To Watch Guide (go to: http://www.iotogo.com/StocksToWatch) provides investors with essential information on stocks that may be poised for a significant move. By featuring... More...>> |
| 10/11/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals Announces Investor Teleconference and Webcast
EMERYVILLE, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will webcast a teleconference with management to provide a general business update on Monday, October 12, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Interested parties may access a live... More...>> |
| 09/30/2009 | 2:00AM | PRNUS | Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of
Preliminary Results Require Further Analysis and Interpretation
WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University... More...>> |
| 09/24/2009 | 1:22PM | PRNUS | Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will webcast an investor briefing on Wednesday, September 30, 2009, beginning at 10:00 a.m. Eastern Time. Speakers will review clinical data for Nexavar in breast cancer presented at the 15th European... More...>> |
| 09/23/2009 | 6:30AM | PRNUS | Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advan
BERLIN, Sept. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar (sorafenib) tablets in combination... More...>> |
| 09/04/2009 | 3:21PM | PRNUS | Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
EMERYVILLE, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, at 10:55 a.m. Eastern Time. Interested parties may access a live webcast of the presentation on our... More...>> |
| 09/02/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
EMERYVILLE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at two healthcare conferences in September.
Robert W. Baird & Co. 2009 Health Care Conference
Onyx will present at the Robert W. Baird & Co. 2009 Health Care Conference in New York, New... More...>> |
| 08/04/2009 | 4:26PM | PRNUS | Onyx Pharmaceuticals Announces Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of
EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it intends to offer, subject to market and other conditions, four million shares of its common stock and $200 million aggregate principal amount of its convertible senior notes due 2016 in concurrent underwritten... More...>> |
| 08/04/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals Reports Second Quarter 2009 Financial Results; Nexavar Global Net Sales Reach $201 Million, 19% Increase Ov
Strong Topline Growth for Nexavar Drives Continued Profitability
EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today reported its financial results for the second quarter 2009. Global Nexavar net sales as reported by Onyx's collaborator Bayer HealthCare Pharmaceuticals... More...>> |
| 07/29/2009 | 4:00PM | PRNUS | Onyx Pharmaceuticals Announces Second Quarter 2009 Financial Results Teleconference and Webcast
EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will webcast a teleconference with management to provide a general business overview, as well as to discuss second quarter 2009 financial results, on Tuesday, August 4, 2009, at 5:00 p.m. Eastern Time... More...>> |
| 06/02/2009 | 4:10PM | PRNUS | Onyx Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference on Tuesday, June 9, at 10:10 a.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website... More...>> |
| 06/01/2009 | 8:00AM | PRNUS | Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
WAYNE, N.J. and EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar(R) (sorafenib) tablets in patients with non-squamous... More...>> |
| 05/28/2009 | 8:00AM | PRNUS | Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y., May 28
/PRNewswire-FirstCall/ -- Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R... More...>> |
| 05/20/2009 | 7:28AM | PRNUS | Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
- First and only oral targeted therapy to significantly improve overall survival in patients with the disease -
WAYNE, N.J. and EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the Ministry of Health, Labour and Welfare... More...>> |
| 05/17/2009 | 10:00AM | PRNUS | Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
Asserts Rights to Phase 2 Anti-Cancer Compound Discovered During Joint Research
EMERYVILLE, Calif., May 17 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights... More...>> |
| 05/14/2009 | 6:00PM | PRNUS | Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
WAYNE, N.J. and EMERYVILLE, Calif., May 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society of Clinical Oncology (ASCO... More...>> |
|